bibliographicCitation |
Quan H, Xu Y, Lou L. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer. 2008 Apr 15;122(8):1730–7. doi: 10.1002/ijc.23262. PMID: 18074350. |